Abstract: The present application relates to a pharmaceutical composition for use in a method of treating diabetes in a human or animal subject in need thereof, to transplantation devices comprising the pharmaceutical composition of the present invention and to methods of treating diabetes using the pharmaceutical composition and transplantation device of the present invention.

Abstract: The present invention relates to a cytotoxic agent for the prophylaxis and/or treatment of a viral infection which is configured for the selective binding to a membrane receptor of virus-infected T lymphocytes, a pharmaceutical composition containing said cytotoxic agent, the use of the cytotoxic agent for the prophylaxis and/or treatment of viral infections, a method of finding cytotoxic agents, the use of a membrane receptor of virus-infected T lymphocytes which is overexpressed in comparison to non-infected T lymphocytes for the diagnosis of a viral infection.

Abstract: A method of processing magnetic resonance (MR) data of a sample under investigation, includes the steps of providing the MR data being collected with an MRI scanner apparatus, and subjecting the MR data to a multi-parameter nonlinear regression procedure being based on a non-linear MR model and employing a set of input parameters, wherein the regression procedure results in creating a parameter map of model parameters of the sample, wherein the input parameters (initial values and possibly boundaries) of the regression procedure are estimated by a machine learning based estimation procedure applied to the MR data. The machine learning based estimation procedure preferably includes at least one of at least one neural network and a support vector machine. Furthermore, an MRI scanner apparatus is described.

Abstract: The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (??-TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-??-TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) to reduce ?? T cells in the subject relative to ?? cells in the subject are provided.

Abstract: The present invention relates to a nucleic acid molecule which encodes a splice variant of the human P2RX7 receptor, and nucleic acid molecules derived therefrom, a recombinant vector containing said nucleic acid molecules, a host containing said recombinant vector, a polypeptide encoded by said nucleic acid molecules, a host cell expressing said polypeptide, a binding molecule binding to said polypeptide, a pharmaceutical composition comprising said binding molecule, a method for the production of the isolated polypeptide, and other methods and uses in connection therewith.

Abstract: The automated determination of an individual function of a DPOAE level map with pdp,I=f(L1, L2) of human or animal hearing. The method may include reading into a main memory a model function with model parameters of a DPOAE level map, based upon a number of N DPOAE measurements of a stimulation frequency pair with respectively different level pairs in a population (p) of a population of normally hearing subjects, automatically presenting n different level pairs of a stimulation frequency pair via tone output means to an individual and detecting the corresponding DPOAE's of the individual via tone recording means, wherein at least the first level pair is predefined, iteratively adapting the model function to the measured n DPOAE's until an individual function is obtained with individual parameters of a DPOAE level map of the individual, outputting the individual function and/or its individual parameters.

Abstract: The present invention relates to fusion proteins comprising a binding protein and an IL-15 polypeptide as well as uses thereof, pharmaceutical compositions comprising such fusion proteins and a method for producing such fusion proteins.

Abstract: A composition for the prophylaxis and/or treatment of a developmental disorder which is associated with preterm birth, and a method for the diagnosis and/or determination and/or prediction of the degree of severity of a developmental disorder which is associated with preterm birth.

Abstract: The invention relates to novel infective agents, the use thereof for the production of a pharmaceutical composition for the treatment and prophylaxes of a disease, preferably an infectious disease, a pharmaceutical composition comprising said compound, and to methods of producing said compounds. The invention further relates to a new probiotic configured for preventing or reducing the colonization by a pathogenic microorganism of an organ of a living being.

Abstract: The present invention relates to a composition for the modulation of the activity of non-structure proteins and a compound contained therein.

Abstract: The present invention is in the field of the cultivation of biological cells and tissues with organ-like function on a microphysiological scale and provides a method for the microphysiological co-cultivation of 3D organoid tissue and at least one 2D cell layer.

Abstract: The present invention relates to the finding that an until now orphan protein named receptor-like protein 1 (RLP1) in plants mediates an immune response to bacterial infections. Specifically, the invention relates to RLP1, now named receptor of enigmatic microbe-associated molecular pattern (MAMP) of Xanthomonas (REMAX), in Arabidopsis thaliana. REMAX was found to recognise the presence of Xanthomonas and to initiate an immune signalling that eventually yields into a typical plant immune responses to bacterial infections. Furthermore, the invention relates to chimeric pattern recognition receptors (PRRs) composed of the extracellular domain of REMAX, which is the recognition site for sensing infection, and c-terminal portions of PRRs of other plant species. Also provided is a method to modulate the immune response of a plant to a bacterial infection by either increasing or decreasing the expression of REMAX or REMAX-like proteins, or the inventive chimeric PRRs in plants.

Abstract: The present invention relates to a method for the production of recombinant expression vectors, a kit adapted to carrying out the method, a vector used in the context of the method, a cell containing such vector and the use of the vector.

Abstract: In a hearing aid (26) that can be inserted into the ear canal (12) of a patient, comprising an actuator (31) effecting a mechanical stimulation of the tympanic membrane (14), the actuator (31) comprises an inner surface (32) associated with the tympanic membrane (14) and an outer surface (42) associated with the ear canal (12) and is configured as an areal disk actuator, whose deformation stimulates the tympanic membrane (14) by areal deformation. On the actuator (31) at a distance from the outer surface (42) a cover plate (43) is arranged which together with the outer surface (42) delimits a preferably lenticular cavity (48).

Abstract: The invention relates to a plant having increased resistance to pathogens, wherein the protein SOBIR1 from Arabidopsis thaliana or a homologous protein, which is capable of interacting with at least one of the PRR receptor proteins RLP30 or RLP1, and at least one of the PRR receptor proteins RLP30 or RLP1 are overexpressed in comparison with the wild-type plant or are newly synthesized. The pathogens are preferably fungi, in particular from the genus Sclerotinia, and bacteria, in particular from the genus Xanthomonas. The invention further relates to a method for producing a plant having increased resistance to pathogens.

Abstract: The present invention relates to a method for the visual examination of biological material ex vivo and an apparatus for the sterical orientation of biological material which can be used in said method.

Abstract: The present invention relates to novel compounds useful for visualizing cell senescence in vitro and in vivo, the preparation of said compounds and their use. In particular, the present invention pertains to novel hexose and particularly galactose derivatives which are useful as senescence tracers in vitro and in vivo.

Abstract: The present disclosure relates to the field of medical technology and in particular to the field of transcranial magnetic stimulation. A coil assembly is presented comprising a housing; a magnetic coil, and an electrode arrangement; wherein the magnetic coil is arranged in the housing and is adapted for generating a magnetic field for transcranial magnetic stimulation, wherein the electrode arrangement is arranged on the housing and adapted for deriving an EEG signal, and wherein the magnetic coil and the electrode arrangement are arranged on top of each other. Further, an electrode arrangement and a system for transcranial magnetic stimulation are provided.

Abstract: The present invention relates to myeloid-derived suppressor cells (MDSC) and exosomes derived therefrom (MDSC exo) and application thereof.

Abstract: The present invention relates to a nucleotide-modified messenger RNA for the permanent correction of a genetic alteration on a DNA. The invention further relates to a nucleotide-modified messenger RNA in combination with a repair template. It also relates to a pharmaceutical composition. It finally relates to methods for the correction of a genetic alteration on a DNA.